Medical Device Reportability Assessment & MDR Reporting Support

For FDA MDR reporting, a manufacturer generally must report when it becomes aware of information that reasonably suggests a device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if it recurred. A proper assessment reviews event details, device involvement, seriousness, malfunction significance, and available investigation findings.

MDR reportability is the process of determining whether a complaint, adverse event, or device malfunction meets the legal threshold for submission under Medical Device Reporting requirements. It involves evaluating the facts of the event, the device's role, patient outcome, recurrence risk, and applicable regulatory definitions. The goal is to produce a timely, documented, and defensible reporting decision supported by complaint and investigation records.

A sound assessment typically uses the complaint record, device identification, event narrative, patient outcome, investigation status, prior similar events, risk documentation, and any available clinical or technical evidence. Reviewers also check whether the event reflects a malfunction, labeling issue, use error, or product quality problem. Complete documentation is essential because reportability decisions must be justified clearly if reviewed during an inspection or audit.

Reportability should be evaluated as soon as a manufacturer becomes aware of potentially relevant information. Early triage is critical because complaint intake delays can compress statutory reporting timelines and weaken investigation quality. A disciplined process usually includes immediate intake review, prompt escalation of serious events, documented decision checkpoints, and follow-up when new facts emerge. Fast initial assessment helps preserve compliance even when investigations are still ongoing.

Yes. A malfunction can still be reportable if it would be likely to cause or contribute to a death or serious injury were it to recur. That means the assessment cannot stop at the absence of actual harm in the reported event. Reviewers must evaluate the device function, foreseeable recurrence, severity of potential outcome, and whether existing controls meaningfully reduce the risk.

Complaint handling is often the starting point for MDR decisions because complaints provide the intake pathway for adverse events, malfunctions, and field issues. A compliant system should classify complaints accurately, trigger timely investigations, escalate potentially reportable events, and maintain closure records that support the final rationale. Weak complaint governance can lead to missed reports, inconsistent decisions, poor trending, and inspection findings tied to post-market controls.

Yes. Non-report decisions should still be documented with a clear rationale, supporting facts, and references to the applicable criteria used in the assessment. Regulators and auditors often review these records to confirm that the manufacturer applies reportability standards consistently. A defensible file usually includes the event summary, seriousness evaluation, malfunction analysis, investigation status, and the reasoning behind why the event did not meet reporting thresholds.

Yes. Elexes supports both one-time reportability reviews and ongoing operational models through complaint governance, PMS support, virtual RAQA services, and regulatory outsourcing. That means manufacturers can get help with intake triage, decision documentation, MDR drafting, authority follow-up, trend review, and integration with CAPA and risk management. This is especially useful for teams managing growing complaint volumes or limited in-house RAQA capacity.